11th Annual Conference Of The British HIV Association [BHIVA]


20–23 April 2005, Burlington Hotel·Dublin·Ireland


Print this article
[TITLE:] IDENTIFYING THE KEY BELIEFS INFLUENCING UPTAKE AND ADHERENCE TO HAART: FINAL RESULTS OF A 12-MONTH PROSPECTIVE, FOLLOW-UP STUDY

[AUTHOR(S):] R Horne, V Cooper, G Gellaitry, M Fisher
Centre for Health Care Research, University of Brighton and Royal Sussex County Hospital, Brighton, UK

BHIVA Conf 2005 Apr 20-23;11:O31


OBJECTIVE: To examine the utility of a necessity-concerns framework in explaining uptake and adherence to HAART.

METHODS: Patients attending Brighton clinics from 2000–2003 who were not taking HAART were referred to this study by their HIV doctor. Of 322 patients recruited, 153 were recommended HAART. Validated questionnaires investigating beliefs about personal necessity of HAART and concerns about adverse effects were completed following a treatment offer. Those who subsequently accepted HAART (n=120) were followed up after 1, 3, 6 and 12 months of treatment.

RESULTS: Limb fat by DEXA was similar for the two groups at baseline. Comparisons of results at baseline and at 48 weeks are given below. Limb fat increased significantly in both groups (P<0.01) but with no difference between the groups (P=0.36). CT scan showed reductions in visceral fat and increases in subcutaneous fat that were similar for both groups (P=0.32 & P=0.78 respectively). Viral load suppression was similarly maintained by ABC and TDF(P=0.16). Ten patients discontinued study drug, 1 on TDF, 9 on ABC (3 with hypersensitivity reactions). Changes in cholesterol and LDL significantly favoured TDF (P=0.01 & 0.05 respectively). A pre-planned subanalysis of response according to thymidine analogue will be presented.

CONCLUSIONS: Switching from a thymidine analogue to tenofovir achieves similar resolution of lipoatrophy, better reduction in lipids, and fewer treatment discontinuations than switching to abacavir.

PRESENTING AUTHOR: R Horne

Download Presentation

2005-04-20
O31

Copyright © 2005 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD